James R. Porter

1.3k total citations
12 papers, 483 citations indexed

About

James R. Porter is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, James R. Porter has authored 12 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Organic Chemistry and 3 papers in Computational Theory and Mathematics. Recurrent topics in James R. Porter's work include Heat shock proteins research (5 papers), Computational Drug Discovery Methods (3 papers) and Cancer therapeutics and mechanisms (2 papers). James R. Porter is often cited by papers focused on Heat shock proteins research (5 papers), Computational Drug Discovery Methods (3 papers) and Cancer therapeutics and mechanisms (2 papers). James R. Porter collaborates with scholars based in United States. James R. Porter's co-authors include Christian Fritz, Kristopher M. Depew, Emmanuel Normant, Jie Ge, Michael J. Brody, Kip A. West, Vito J. Palombella, Julian Adams, J. Jack Lee and Yun Gao and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

James R. Porter

12 papers receiving 459 citations

Peers

James R. Porter
Lori K. Gavrin United States
Brian Zifcak United States
Su-Jun Deng United States
Jason Boggs United States
Christine Fernandes United States
Zofia M. Kiliańska Poland
Olga Abramczyk United States
Lynn Wood United Kingdom
Laura A. Lopez-Garcia Germany
Lori K. Gavrin United States
James R. Porter
Citations per year, relative to James R. Porter James R. Porter (= 1×) peers Lori K. Gavrin

Countries citing papers authored by James R. Porter

Since Specialization
Citations

This map shows the geographic impact of James R. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Porter more than expected).

Fields of papers citing papers by James R. Porter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Porter. The network helps show where James R. Porter may publish in the future.

Co-authorship network of co-authors of James R. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Porter. A scholar is included among the top collaborators of James R. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Porter. James R. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Pelish, Henry E., Anupong Tangpeerachaikul, Nancy E. Kohl, et al.. (2021). Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation. Cancer Research. 81(13_Supplement). 1465–1465. 4 indexed citations
2.
Pelish, Henry E., Anupong Tangpeerachaikul, Nancy E. Kohl, et al.. (2021). Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation. Cancer Research. 81(13_Supplement). 1468–1468. 22 indexed citations
3.
Flinn, Ian W., Steven M. Horwitz, Manish R. Patel, et al.. (2012). Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies. Blood. 120(21). 3663–3663. 19 indexed citations
4.
Porter, James R., Christian Fritz, & Kristopher M. Depew. (2010). Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Current Opinion in Chemical Biology. 14(3). 412–420. 156 indexed citations
5.
Porter, James R., Jie Ge, J. Jack Lee, Emmanuel Normant, & Kip A. West. (2009). Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy. Current Topics in Medicinal Chemistry. 9(15). 1386–1418. 55 indexed citations
6.
Douglas, Mark, Alice R. Lim, James R. Porter, et al.. (2009). The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activityin vivo. Molecular Cancer Therapeutics. 8(12). 3369–3378. 14 indexed citations
7.
Fritz, Christian, Bonnie Tillotson, Jie Ge, et al.. (2008). 148 POSTER Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors. European Journal of Cancer Supplements. 6(12). 48–48. 3 indexed citations
8.
Ge, Jie, Emmanuel Normant, James R. Porter, et al.. (2006). Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90. Journal of Medicinal Chemistry. 49(15). 4606–4615. 143 indexed citations
9.
Kurosu, Michio, James R. Porter, & Michael A. Foley. (2003). An efficient synthesis of indane-derived bis(oxazoline) and its application to hetero Diels–Alder reactions on polymer support. Tetrahedron Letters. 45(1). 145–148. 23 indexed citations
10.
11.
Porter, James R.. (1999). Formation of Carbon-Carbon Bonds Using Iron Tricarbonyl-(η4-cyclobutadienyl)-Stabilized Carbonium Ions. Synthesis. 1999(S1). 1407–1410. 5 indexed citations
12.
Brody, Michael J., et al.. (1984). Role of Central Catecholaminergic Systems in Pathogenesis and Treatment of Hypertension. Journal of Cardiovascular Pharmacology. 6. S727–741. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lori K. Gavrin Breakdown of academic impact, for papers by Brian Zifcak Breakdown of academic impact, for papers by Su-Jun Deng Breakdown of academic impact, for papers by Jason Boggs Breakdown of academic impact, for papers by Christine Fernandes Breakdown of academic impact, for papers by Zofia M. Kiliańska Breakdown of academic impact, for papers by Olga Abramczyk Breakdown of academic impact, for papers by Lynn Wood Breakdown of academic impact, for papers by Laura A. Lopez-Garcia
Rankless by CCL
2026